OpenAI’s venture-capital arm and Peter Thiel’s Founders Fund have each committed capital to Coherence Neuro, a San Francisco startup building a brain-implant platform for cancer detection and treatment. The money forms part of a $45 million seed financing round, underscoring growing interest among large technology firms in neural data and medical-device applications.
Coherence Neuro’s approach pairs brain-computer-interface hardware with artificial-intelligence models that can parse the massive streams of raw neural activity generated by the implant. According to CEO Ben Woodington, AI is uniquely suited to translate subtle electrical patterns into actionable information, such as identifying whether a tumor is expanding, shrinking, or re-emerging, a task beyond human analysts.
Thiel’s venture portfolio already includes Elon Musk’s Neuralink and the wrist-band technology from CTRL-labs, which Facebook acquired in 2019. Those prior investments illustrate a broader strategy of supporting companies that bridge neural sensing hardware with advanced computational techniques, a trend that Coherence Neuro now joins.
Pre-clinical work at Coherence has demonstrated the ability to recognize tumor-related signals in animal models, allowing the system to infer the growth trajectory of brain cancers. The company reports that its algorithms can differentiate between active disease and regression, providing a potential early-warning system that could inform therapeutic decisions.
In the summer, the firm conducted a brief safety assessment at the Royal Melbourne Hospital, placing the implant in the brains of three patients undergoing tumor resection. The device remained in situ for roughly thirty minutes before removal, offering an initial verification that the hardware can be introduced without immediate adverse effects.
Following that pilot, Coherence has expanded testing to seven additional participants, this time evaluating both recording and stimulation functions. The dual-mode study aims to confirm that the implant can not only capture neural signatures of cancer but also deliver low-intensity electrical pulses intended to disrupt tumor growth.
With the new capital, Coherence plans to launch a longer-term clinical trial that will leave the device implanted in patients diagnosed with glioblastoma, an aggressive form of brain cancer. The trial will assess the system’s ability to continuously monitor tumor activity and provide on-demand therapeutic stimulation, while the company also eyes extensions to other cancer sites.
Woodington emphasized that OpenAI’s investment does not include any rights to the neural or health data generated by the implant. “There’s nothing in the contracts or arrangements that would mean that we would share, or they would have access to, any brain data or other health data that we’re generating,” he told WIRED.